With 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investors [Yahoo! Finance]
Neurogene Inc. (NGNE)
Company Research
Source: Yahoo! Finance
Insiders own 11% of Neurogene Every investor in Neurogene Inc. ( NASDAQ:NGNE ) should be aware of the most powerful shareholder groups. With 32% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's delve deeper into each type of owner of Neurogene, beginning with the chart below. See our latest analysis for Neurogene What Does The Institutional Ownership Tell Us About Neurogene? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional i
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesBusiness Wire
- Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingBusiness Wire
- Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
NGNE
Earnings
- 5/10/24 - Beat
NGNE
Sec Filings
- 5/10/24 - Form 10-Q
- 5/10/24 - Form 8-K
- 5/7/24 - Form 8-K
- NGNE's page on the SEC website